Biotech Sector Considers New Funding Vehicle: FDA Priority Review Voucher
Big Pharma execs say vouchers may be worth $100 million to $200 million. Two small-cap biotechs among those hoping to cash in.
Big Pharma execs say vouchers may be worth $100 million to $200 million. Two small-cap biotechs among those hoping to cash in.